| ARMATA PHARMACEUT. |
| USA |
| Gesundheit |
| US04216R1023 / A2PKLC |
| TG1N (Frankfurt) |
| FRA:TG1N, ETR:TG1N, TG1N:GR |
| - |
| https://www.armatapharma... |
|
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company’s current work centers on ph..
>Volltext.. |
| 172.47 Mio. EUR |
| 422.5 Mio. EUR |
| 4.78 Mio. EUR |
| -28.84 Mio. EUR |
| -165.69 Mio. EUR |
| -4.57 EUR |
| 270.68 Mio. EUR |
| 20.65 Mio. EUR |
| -21.92 Mio. EUR |
| 0.1 |
| -19.29% |
| -647.57% |
| - |
| - |
| - |
| - |
| ARMATA |
| 15.09.26 |
|